Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two RNAi-Related Patent Applications: Jan 10, 2008

Premium
Title: Methods for Expression of Small Antiviral RNA Molecules Within a Cell
 
Number: 20080003658
 
Filed: March 21, 2007
 
Lead Inventor: Xiao-Feng Qin, California Institute of Technology
 
The patent application, its abstract states, claims “methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double-stranded RNA complexes. Small interfering RNA can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that,” it adds.
 
The application also describes “methods for treating patients … suffering from infection, particularly infection with HIV,” the abstract states. “In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.”
 

 
Title: Methods for Expression of Small Antiviral RNA Molecules With Reduced Cytotoxicity Within a Cell
 
Number: 20080003682 
 
Filed: March 8, 2007
 
Lead Inventor: Carlos Lois-Caballe, California Institute of Technology
 
According to the patent application’s abstract, the invention comprises “methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. Small interfering RNA can be expressed using the methods of the invention within a cell.”
 
The abstract adds that the invention also comprises “methods for producing [a] siRNA-encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In … a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell,” it adds. “The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.”

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.